---
document_datetime: 2024-09-23 16:57:48
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/aripiprazole-sandoz-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: aripiprazole-sandoz-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.8304611
conversion_datetime: 2025-12-22 19:39:42.712241
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Aripiprazole Sandoz

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0031               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                 | 20/09/2024                          |                                             | PL                               |           |
| IB/0030              | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement | 31/07/2024                          | n/a                                         |                                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                   | or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                  |            |            |             |                                                                                                               |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------|
| PSUSA/234/2 02307 | Periodic Safety Update EU Single assessment - aripiprazole                                                                                                                                                                                                   | 07/03/2024 | n/a        |             | PRAC Recommendation - maintenance                                                                             |
| N/0029            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 11/12/2023 |            | PL          |                                                                                                               |
| IA/0027           | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                             | 14/09/2023 | n/a        |             |                                                                                                               |
| IB/0026           | B.II.z - Quality change - Finished product - Other variation                                                                                                                                                                                                 | 22/12/2022 | n/a        |             |                                                                                                               |
| IA/0025           | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                  | 31/10/2022 | n/a        |             |                                                                                                               |
| IB/0023           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 01/09/2022 | 12/10/2022 | SmPC and PL | To update SmPC section 4.8 by adding \"blood prolactin decreased\" in the tabulated lists of adverse reactions. |
| IB/0022/G         | This was an application for a group of variations.                                                                                                                                                                                                           | 13/06/2022 | n/a        |             |                                                                                                               |

<div style=\"page-break-after: always\"></div>

|           | applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |             |         |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------|
| IA/0021   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 17/03/2022 | n/a        |             |         |
| IA/0020   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 12/11/2021 | n/a        |             |         |
| IB/0018/G | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by | 26/10/2021 | 12/10/2022 | SmPC and PL | the MAH |
| IA/0019/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 20/10/2021 | n/a        |             |         |

<div style=\"page-break-after: always\"></div>

|                   | B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information   |            |            |                                  |                                                                                                                                                                                                                                                                                   |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0017           | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 22/07/2021 | n/a        |                                  |                                                                                                                                                                                                                                                                                   |
| PSUSA/234/2 02007 | Periodic Safety Update EU Single assessment - aripiprazole                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 11/02/2021 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                 |
| IA/0016           | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 23/10/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                                   |
| R/0014            | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 30/04/2020 | 26/06/2020 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Aripiprazole Sandoz in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/234/2       | Periodic Safety Update EU Single assessment -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 27/02/2020 | 28/04/2020 | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| 01907             | aripiprazole                                                                                                                                                                                                                                                 |            |            |                        | the variation to terms of the Marketing Authorisation(s)' for PSUSA/234/201907.                                                          |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0013           | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                  | 12/12/2019 | n/a        |                        |                                                                                                                                          |
| PSUSA/234/2 01807 | Periodic Safety Update EU Single assessment - aripiprazole                                                                                                                                                                                                   | 28/02/2019 | 29/04/2019 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/234/201807. |
| IB/0011           | B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test                                                                                                     | 30/10/2018 | n/a        |                        |                                                                                                                                          |
| IB/0009           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 15/02/2018 | 16/03/2018 | SmPC, Labelling and PL |                                                                                                                                          |
| PSUSA/234/2 01707 | Periodic Safety Update EU Single assessment - aripiprazole                                                                                                                                                                                                   | 08/02/2018 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                        |
| IAIN/0007         | B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer                                                                      | 13/09/2017 | n/a        |                        |                                                                                                                                          |
| IB/0005           | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                                                                                   | 11/04/2017 | 16/03/2018 | Annex II               |                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                   | authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                        |                                   |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| PSUSA/234/2 01607 | Periodic Safety Update EU Single assessment - aripiprazole                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 09/02/2017 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0004           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                      | 09/12/2016 | 16/02/2017 | SmPC and PL            |                                   |
| IB/0002           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                      | 04/07/2016 | 16/02/2017 | SmPC, Labelling and PL |                                   |
| IB/0001/G         | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO | 17/03/2016 | 16/02/2017 | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

| the MAH   |
|-----------|